

Medicine Protocol for the Administration of MMR (Measles, Mumps and Rubella) live vaccine MMR VAXPRO by registered nurses and registered midwives




This medicine protocol is a specific written instruction for the administration of MMRVAXPRO vaccine to children/students in first year in Primary and Second Level School by registered nurses and registered midwives. **This medicine protocol is valid for the 2020/2021 HSE School Immunisation Programme.**

This medicine protocol enables registered nurses and midwives employed in the voluntary and statutory services of the HSE who have undertaken the required education and training programmes to administer MMRVAXPRO measles, mumps and rubella (live) vaccine with reference to and guidance from Nursing & Midwifery Board of Ireland, National Nursing and Midwifery Immunisation Working Group, National Immunisation Advisory Committee, National Immunisation Office, HSE and in accordance with the Summary of Product Characteristics for MMRVAXPRO vaccine as detailed by the Health Products Regulatory Authority at www.hpra.ie :

- An Bord Altranais (2007) *Guidance to Nurses and Midwives on Medication Management* Dublin: An Bord Altranais
- Health Services Executive (2019) *Directions for Nurses and Midwives for the Management of a Patient who Develops Anaphylaxis or suspected anaphylaxis incorporating Medicine Protocol for the administration of Epinephrine (Adrenaline) injection BP 1:1000 by intramuscular injection for nurses and midwives for the management of a patient with anaphylaxis or suspected anaphylaxis.* Dublin: Health Service Executive
- National Immunisation Office 2020. Supporting Information for Staff: Schools Immunisation Programme :Health Service Executive 2020/2021available at <https://www.hse.ie/eng/health/immunisation/pubinfo/schoolprog/4in1mmr/schoolguidelines.pdf>
- National Immunisation Advisory Committee *Immunisation Guidelines for Ireland* Dublin: Royal College of Physicians of Ireland National Immunisation Advisory Committee (*Online Update available at <https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/>*)
- Nursing and Midwifery Board of Ireland (2014) *Code of Professional Conduct and Ethics for Registered Nurses and Registered Midwives.* Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Code>.
- Nursing and Midwifery Board of Ireland (2015) *Practice Standards for Midwives.* Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Midwives-Standards>.
- Nursing and Midwifery Board of Ireland (2015) *Recording Clinical Practice. Guidance to Nurses and Midwives.* Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/More-Standards-Guidance/Recording-Clinical-Practice>
- Nursing and Midwifery Board of Ireland (2015) *Scope of Nursing and Midwifery Practice Framework.* Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Scope-of-Practice/Nursing-Practise-Scope-Definition>

The Nursing and Midwifery Board of Ireland defines medicine protocols as “written directions that allow for the supply and administration of a named medicinal product by a nurse or midwife in identified clinical situations. A medicine protocol involves the authorisation of the nurse/midwife to supply and administer a medicine to groups of patients in a defined situation meeting specific criteria and who may not be individually identified before presentation for treatment. An individually named prescription is not required for the supply and administration of medication when a medication protocol is in effect” (An Bord Altranais, 2007).

Medicine Protocol for the Administration of MMRVAXPRO vaccine by registered nurses and midwives to children/students in Primary/ Second Level School through a School Immunisation Programme

Document reference number:	ONMSD 2020-008
1.0 Critical Elements	
Name of Organisation where protocol applies	Health Service Providers across the voluntary and statutory services of the Health Service Executive (HSE). This Medicine Protocol applies to: <ul style="list-style-type: none"> Registered nurses and midwives involved in the supply and administration of the MMRVAXPRO vaccine to children/students in primary/second level school through a School Immunisation Programme.
Date the protocol comes into effect	September 2020
Date for review of protocol	May 2021
Document prepared by:	Office of the Nursing and Midwifery Services Director (ONMSD) HSE, in collaboration with the National Immunisation Office (NIO) at the request of Dr Lorraine Doherty, National Clinical Director Health Protection.
Names and Signatures of the employing authority who is authorising the implementation of the protocol <i>"On behalf of the authority employing professionals authorised to administer under this medicine protocol, I have read this medicine protocol and authorise its implementation"</i>	Name: Dr. Lorraine Doherty , National Clinical Director Health Protection, HSE Signature:  Name: Dr Colm Henry , Chief Clinical Officer, HSE Signature:  Name: Dr Geraldine Shaw , Nursing and Midwifery Services Director, HSE Signature: 

2.0 Clinical Criteria	
Clinical Condition for use of the protocol	The clinical condition for which this medicine protocol has been developed is for the active immunisation against and prevention of Measles, Mumps and Rubella infection.
Circumstances in which the medicine protocol applies	<p>The School Immunisation Programme (SIP) will be delivered annually by the Health Service Executive (HSE)</p> <p>The aim of the immunisation programme is to complete the measles, mumps and rubella vaccination programme. The MMR vaccine is recommended for all children at 12 months of age and at 4-5 years in the Immunisation Guidelines for Ireland https://www.hse/eng/health/immunisation/hcpinfo/guidelines/.</p> <p>If a child has not received a 1st dose of MMR vaccine, MMRVAXPRO (MMR) should be given, under this protocol, to a child in junior infants or age equivalent. A 2nd dose of MMR vaccine should then be given at least 4 weeks after the 1st MMR (MMRVAXPRO) dose. – Preferably in a SIP mop up clinic.</p> <p>This medicine protocol also applies in MMRVAXPRO catch up campaigns and outbreaks situations as recommended by NIAC (2014)</p>
Inclusion criteria for children/service user treatment using the medicine protocol	<p>Children/students in primary/second level school or age equivalent in special schools and home schooled students.</p> <p>https://www.hse.ie/eng/health/immunisation/pubinfo/schoolprog/4in1mmr/schoolguidelines.pdf</p> <p>Children/Students with valid consent.</p>
Exclusion criteria for children using the medicine protocol	<p>A known history of anaphylactic or hypersensitivity reaction to MMRVAXPRO or any of the MMRVAXPRO vaccine constituents including neomycin or gelatin.</p> <p>Acute febrile illness: The presence of a minor infection such as a mild upper respiratory infection or low grade fever is not a contraindication to immunisation.</p> <p>Child/student with a history of thrombocytopenia within six weeks of receiving first dose MMRVAXPRO vaccine.</p> <p>Child/student with a contraindication to intramuscular injection (haematological disorder/coagulation disorder e.g. haemophilia, severe thrombocytopenia).</p> <p>Child/student who are immunocompromised either due to disease or treatment.</p> <p>MMR vaccine should not be given from 2 weeks before to 3- 11 months after specific immunoglobulins as they may interfere with the immune response</p> <p>MMR should not be given 2 weeks before Human Normal Immunoglobulin (HNIG).</p> <p>Child/student who have received varicella or yellow fever live vaccine within the previous 4 weeks.</p> <p>Active untreated tuberculosis.</p> <p>Pregnancy where applicable.</p>
Actions to be taken for those who are excluded from the Protocol	<ul style="list-style-type: none"> • All children/students meeting exclusion criteria must be referred to the medical practitioner for an individual medical assessment. • Document action in clinical notes. • Where MMRVAXPRO vaccine is prescribed following medical assessment, the

	<p>nurse or midwife may administer MMRVAXPRO vaccine within their scope of practice.</p> <p><i>Note: In determining their scope of practice, nurses and midwives must make judgements about their competency to carry out a role or activity (NMBI, 2015).</i></p>
Description of circumstances and referral arrangements when further advice or consultation is required	<p>Discuss the student with the Medical Practitioner or lead nurse in the event of:</p> <ul style="list-style-type: none"> • Previous Adverse reaction • Other clinical concerns
Documentation required for the implementation of this medicine protocol	<p>A Consent form must be completed by the parent/legal guardian for all children/students who receive the MMRVAXPRO vaccine. Students aged 16 years and over consent on their own behalf. Appropriate details including the batch number must be recorded on the Consent Form.</p> <p>The following documents will be required at each school vaccination session:</p> <ul style="list-style-type: none"> • Vaccination session report forms • Blank Vaccine consent forms • Patient held record cards • Health Products Regulatory Authority Adverse Reaction Reporting forms • HSE Incident/near miss report forms (NIRF, 2020) • Tear pads for after vaccination <p>It is the responsibility of each nurse or midwife to be familiar with the appropriate documentation to support the safe administration of MMRVAXPRO vaccine which includes the following:</p> <ul style="list-style-type: none"> • Information for Staff: School Immunisation Programme 2020/2021 • Medicine Protocol for the administration of measles, mumps, and mumps (live) vaccine, MMRVAXPRO by registered nurses and registered midwives to children/students in primary/second level school or equivalent (e.g. home schooled, special schools) through the School Immunisation Programme. • Directions for nurses and midwives for the management of a patient who develops anaphylaxis or suspected anaphylaxis incorporating <i>Medication Protocol for the Administration of Epinephrine (adrenaline) Injection BP 1:1000 by intramuscular injection by nurses and midwives for the management of a patient with anaphylaxis or suspected anaphylaxis (HSE 2019)</i> available at https://www.hse.ie/eng/health/immunisation/hcpinfo/fluinfo/adrenalineprotocol.pdf
3.0 Name of Medicine	<p>MMRVAXPRO: Dosage 0.5ml Site Deltoid (right side recommended) Route IM</p>
Link to Medicine Details of product information and other data including instructions for supply and administration is available from the Health Products Regulatory Authority at www.hpra.ie	<p>2020/2021 Link to Summary of Product Characteristics and PIL https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000604/WC500030170.pdf</p> <p>Link to Patient Information Leaflet https://www.hpra.ie/docs/default-source/vaccine-pils/mmrvoxpro-pil.pdf?sfvrsn=6</p>
Procedure for the	In the case of medicine errors that directly involve the child/student, i.e. wrong

<p>reporting and documentation of errors and near misses involving the medication</p>	<p>medicine/patient/dose/route being administered or another medicine error, the registered nurse or registered midwife must remain with the child/student and closely monitor them for any adverse reactions.</p> <p>Vital signs should be recorded and the student should be reviewed by the registered nurse/midwife and/ or medical practitioner.</p> <p>The incident must be reported to the relevant line manager as soon as possible.</p> <p>The incident and all actions taken must be promptly recorded and the relevant National Incident Management Report Form completed (National Incident Report Form (NIRF--01-V 11 March 2020)</p> <p>https://www.hse.ie/eng/about/gavd/incident-management/nirf-01-v11-person.pdf</p> <p>The incident and all actions taken must be promptly recorded in the child/student's documentation/notes and the relevant report form completed.</p> <p>The child/ student's parent and/or legal guardian must be informed of the incident.</p> <p>An incident report form must be completed by the registered nurse or registered midwife and forwarded to the relevant line manager as per local policy.</p> <p>Any suspected adverse reactions associated with medication errors should be reported to the HPRA as outlined below.</p> <p>Any errors and near misses not involving medication e.g. needle stick injuries, the incident and all actions taken must be promptly recorded on the relevant National Incident Management Report form and forwarded to the relevant line manager as per local policy. Refer 'EMI Tool Kit' (https://www.hpsc.ie/a-z/EMIToolkit/).</p>
<p>Procedure for reporting Adverse Drug Reactions to the Health Products Regulatory Authority (HPRA)</p>	<p>The relevant nurse or midwifery staff should report to the HPRA any suspected adverse reactions, in accordance with criteria outlined by the HPRA. This reporting may be carried out in line at https://www.hpra.ie or through use of the yellow care system which is available in the downloadable format from the HPRA website, or on request from the HPRA.</p> <p>The incident and all actions taken must be promptly recorded in accordance with the criteria outlined by the HPRA:- <i>Management of a Patient with Anaphylaxis HSE (2019)</i> – available online at</p> <p>https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/Anaphylaxis.pdf</p>
<p>Resources and equipment required</p>	<ul style="list-style-type: none"> • Vaccine Powder and solvent for solution for injection in a pre-filled syringe • Fridge/Cool box with minimum/maximum temperature recording device to monitor the cold chain temperature (between +2°C and +8°C) • Disposable kidney dishes/coloured trays. • Gauze swabs/Plasters. • Sharps bins and bags for disposal of other hazardous material • Alcohol hand rinse. • Access to telephone. • Resuscitation equipment and drugs in accordance with the <i>Management of a Patient with anaphylaxis</i> (National Immunisation Advisory Committee, 2019) available at https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/Anaphylaxis.pdf • Access to medical support. • Safe storage areas for medicines and equipment. • Current medicine protocol for MMRVAXPRO vaccine.

Audit process to identify appropriate use of the protocol or unexpected outcomes	All documentation will be held for review and audit purposes as per local policy.
4.0 Information for child/student/parent/guardian	
Advice to be given to the child/student/parent/guardian before treatment Advice to be given to the child/student/parent/guardian after treatment	<p>HSE 4 in 1 and MMR vaccine Information for parents of children in Junior infant's booklet must have been supplied with the consent form to each student/parent/legal guardian prior to administration of the vaccine.</p> <p>Obtain informed consent and a signed consent form.</p> <p>After Treatment Information Tear Pad, stating date and time of vaccination must be given to all children/students for parental/guardian's attention. The Tear Pad includes advice about contacting relevant medical personnel in the event of adverse reaction occurring following administration of the vaccination.</p> <p>The child/student must be advised to remain seated in the post vaccination observation area for 15 minutes to allow monitoring of any immediate reaction including possible anaphylactic reaction and must be advised to report any side effects to the registered nurse or registered midwife.</p> <p>Adverse reactions are considerably less common (less than 1%) after the 2nd dose of MMRVAXPRO vaccine.</p>
Details of any necessary follow-up, action and referral arrangements	In the event of an adverse reaction the nurse/midwife must ensure that all procedures are adhered to as outlined in Section 3.
5.0 Staff authorised to use this medicine protocol	
Professional qualifications, training, and competence required prior to using this medicine protocol Professional Qualifications Training and Competence:	Registered nurse or registered midwife on the active register maintained by The Nursing and Midwifery Board of Ireland. National Schools Immunisation programme for registered nurses and registered midwives on the use of this medicine protocol. Basic Life Support for Health Care Providers within the last two years. Initial anaphylaxis programme (<i>"National Anaphylaxis Education Programme for Health Care Professionals"</i>) via HSELand followed by a one and a half hour classroom based skills workshop (replacing the previous four hour classroom based programme). Subsequent updates every two years via HSELand Anaphylaxis e-learning programme available at www.hse.ie . The registered nurse/midwife must complete the <i>"Competency Self - Assessment Tool for registered nurses and registered midwives to supply and administer vaccines under medicine protocols through a schools immunisation programme"</i> . Recommended: E-learning Guide to Medicine Management, available at www.hseland.ie

	<i>Introduction to Immunisation</i> , available at www.hseland.ie
--	---

References

An Bord Altranais (2007) *Guidance to Nurses and Midwives on Medication Management* Dublin: An Bord Altranais.

Health Products Regulatory Authority available at www.hpra.ie (accessed 15th June 2020)

Health Service Executive (2016) E-learning Guide to Medicine Management, available at www.hseland.ie

Health Service Executive (2019) *Directions for Nurses and Midwives for the Management of a Patient who Develops Anaphylaxis or suspected anaphylaxis incorporating Medicine Protocol for the Administration of Epinephrine (Adrenaline) Injection BP 1:1000 by intramuscular injection by nurse and midwives for the management of a patient with anaphylaxis or suspected anaphylaxis*. Dublin: Health Service Executive

Health Service Executive (2010) *Healthcare Risk Waste Management Segregation Packaging and Storage Guidelines for healthcare Risk Waste*. Dublin: Health Service Executive.

MMRVaxPRO Vaccine MSD Ireland Limited *Summary of Product Characteristics and Patient Information Leaflet*. Available at www.hpra.ie

Irish Medicines Board (*Miscellaneous Provision*) Act 2006 (Commencement) Order 2007. Dublin: Stationery Office

Irish Medicines Board (*Miscellaneous Provision*) Act 2006 (No. 3 of 2006) (Section 10(1(ii))). Dublin: Stationery Office

Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2007, Statutory Instruments No. 201 of 2007. Dublin: Stationery Office

Misuse of Drugs (Amendment) Regulations 2017, Statutory Instruments No.173 of 2017. Dublin: Stationery Office

National Immunisation Advisory Committee (2019) *Anaphylaxis: Treatment in the Community*. Available at <https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/Anaphylaxis.pdf>

National Immunisation Advisory Committee *Immunisation Guidelines for Ireland* Dublin: Royal College of Physicians of Ireland National Immunisation Advisory Committee (*Online Update available at* <https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/>

National Immunisation Office (2019) *Information for Staff: School Immunisation Programme: Health Service Executive 2019/2020*

Nursing and Midwifery Board of Ireland (2014) *Code of Professional Conduct and Ethics for Registered Nurses and Registered Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Code>.

Nursing and Midwifery Board of Ireland (2015) *Practice Standards for Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Midwives-Standards>.

Nursing and Midwifery Board of Ireland (2015) *Recording Clinical Practice. Guidance to Nurses and Midwives*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/More-Standards-Guidance/Recording-Clinical-Practice>

Nursing and Midwifery Board of Ireland (2015) *Scope of Nursing and Midwifery Practice Framework*. Dublin: Nursing and Midwifery Board of Ireland available at: <https://www.nmbi.ie/Standards-Guidance/Scope-of-Practice/Nursing-Practise-Scope-Definition>